These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9696655)

  • 1. Effect of troglitazone in type 2 diabetes mellitus.
    Gorson DM
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of troglitazone in type 2 diabetes mellitus.
    Rusk MH
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
    [No Abstract]   [Full Text] [Related]  

  • 3. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y; Wakasugi T; Yagi K; Mabuchi H
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract]   [Full Text] [Related]  

  • 4. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 7. A treatment for Mr WP: thiazolidinediones after troglitazone.
    Montague CT
    Diabet Med; 2002; 19 Suppl 1():7-9. PubMed ID: 11871423
    [No Abstract]   [Full Text] [Related]  

  • 8. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
    Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
    Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
    [No Abstract]   [Full Text] [Related]  

  • 9. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 10. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone directly increases HDL cholesterol levels.
    Nozue T; Michishita I; Minagawa F; Genda A
    Diabetes Care; 1999 Feb; 22(2):355-6. PubMed ID: 10333957
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
    Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
    Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise and fall of troglitazone.
    Bailey CJ
    Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
    [No Abstract]   [Full Text] [Related]  

  • 19. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of troglitazone on lipoprotein(a) levels in obese subjects.
    Tack CJ; Smits P; DeMacker PN; Stalenhoef AF
    Diabetes Care; 1999 Oct; 22(10):1752-3. PubMed ID: 10526754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.